| P/E (FY) | 39.8 | Sales (TTM) | SEK 1.81B |
| Earnings (TTM) | SEK 207.4M | ROE | 18.00% |
| Net Margin | 11.48% | ROIC | 24.80% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 29.14% | Sales Growth 3Y | 25.40% |
MedCap AB is a private equity firm specializing in investments such as later-stage and growth capital, industry consolidation, add-on acquisitions, buyouts, and turnarounds. It favors sectors including biotechnology, life sciences, pharmaceuticals, medtech, and assistive technology, typically targeting small to medium-sized unlisted companies based in the Nordic region and Northern Europe and taking either minority or majority stakes. The firm invests amounts generally ranging from roughly SEK 25 million to SEK 150 million. It was founded in 2001 and is based in Stockholm, Sweden.
| Market Cap | $858.5M | Trading Days | 4112 |
| 52W High | 677.00 |
| 52W Low | 440.00 |
| % Off High | −18.91% |
| YTD | 0.00% | 1Y | −15.67% |
| 3Y | 75.40% | 5Y | 177.55% |
| 10Y | 1468.57% | Since incept. (ann.) | 29.19% |
| Ann. Volatility (1Y) | 35.22% | Ann. Volatility (3Y) | 54.75% |
| Sharpe (1Y) | −0.32 | Sharpe (3Y) | 0.71 |
| Max Drawdown (1Y) | −32.39% | Max Drawdown (3Y) | −45.84% |
| Beta (3Y, vs SPY) | 0.28 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| TALK | Talkspace, Inc. | $872.7M | 130.3 |
| SYNSAM.ST | Synsam AB (publ) | $843.1M | 22.4 |
| MEDCL.PA | MEDINCELL S.A. | $878.9M | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.5M | 9.9 |
| KURA | Kura Oncology, Inc. | $826.5M | — |
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| OMER | OMEROS CORP | $816.4M | — |
| BVS | Bioventus Inc. | $910.4M | 40.0 |
| ODTX |
| $914.0M |
| — |
